Table 1 Signature group demographics and clinical information.

From: Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets

ALL patients

Total

A

B

C

D

E

F

P-value

N = 871

(N = 84)

(N = 51)

(N = 206)

(N = 106)

(N = 227)

(N = 197)

Diagnosis

       

3.66E-44

CLL

795 (91%)

48%

86%

96%

96%

95%

99%

 

HCL

12 (1%)

14%

0%

0%

0%

0%

0%

 

HCLV

4 (0%)

4%

0%

0%

0%

0%

0%

 

LGL-T

4 (0%)

5%

0%

0%

0%

0%

0%

 

MBL

4 (0%)

1%

0%

0%

0%

1%

0%

 

MCL

12 (1%)

5%

4%

1%

1%

1%

0%

 

MZL

12 (1%)

7%

0%

0%

2%

1%

1%

 

PLL

4 (0%)

0%

2%

1%

0%

0%

0%

 

Richters

8 (1%)

4%

2%

1%

1%

0%

0%

 

T-cell PLL

16 (2%)

13%

6%

0%

0%

1%

0%

 

CLL patients

Total

A

B

C

D

E

F

 

N = 795

(N = 40)

(N = 44)

(N = 198)

(N = 102)

(N = 215)

(N = 196)

 

Age (mean + SD)

65 (±10)

63 (±8.6)

64 (±12)

66 (±9.5)

64 (±11)

63 (±11)

66 (±11)

0.01

Race (772 reported)

       

0.84

Asian

7 (1%)

3%

0%

1%

0%

2%

2%

 

Black

33 (4%)

5%

3%

5%

3%

3%

5%

 

Hispanic

22 (3%)

3%

5%

2%

3%

4%

2%

 

White

710 (92%)

89%

92%

92%

94%

91%

91%

 

Gender

       

0.11

Male

485 (61%)

42%

55%

63%

68%

61%

60%

 

Binet stage (784 reported)

       

0.0002

A

478 (61%)

47%

73%

49%

71%

68%

60%

 

B

71 (9%)

6%

2%

15%

4%

6%

10%

 

C

235 (30%)

47%

25%

36%

25%

26%

30%

 

Rai stage (784 reported)

       

4.44E-06

0

268 (34%)

26%

39%

22%

49%

44%

28%

 

I

234 (29%)

18%

32%

34%

18%

28%

37%

 

II

47 (6%)

8%

5%

9%

8%

2%

6%

 

III

132 (17%)

34%

16%

17%

14%

17%

14%

 

IV

103 (13%)

14%

9%

18%

11%

9%

15%

 

Lab tests (mean + SD)

Lymphocytes

38 (±54)

14 (±13)

28 (±27)

56 (±64)

24 (±38)

20 (±31)

54 (±66)

1.74E-31

Hemoglobin

13 (±1.8)

14 (±1.8)

14 (±1.4)

13 (±1.9)

14 (±1.5)

14 (±1.5)

13 (±2.0)

1.67E-04

Serum B2M

2.8 (±1.8)

2.3 (±1.2)

2.7 (±2.9)

3.4 (±2.1)

2.4 (±1.5)

2.4 (±1.1)

2.8 (±1.7)

4.04E-11

Serum LDH

480 (±240)

560 (±260)

500 (±180)

540 (±310)

380 (±140)

390 (±210)

530 (±180)

8.78E-18

IGHV status (576 reported)

       

1.30E-05

Unmutated

280 (49%)

35%

36%

68%

35%

44%

47%

 

ZAP70 Positive (376 reported)

189 (50%)

35%

43%

60%

34%

60%

45%

7.00E-03

SF3B1 Mutated (211 reported)

34 (16%)

20%

10%

28%

15%

12%

13%

0.25

Chromosome abnormalities (715 reported)

Deletion 11Q

100 (14%)

5%

11%

19%

11%

10%

17%

0.03

Deletion 13Q

273 (38%)

28%

45%

31%

47%

41%

40%

0.05

Trisomy 12

109 (15%)

25%

13%

18%

11%

22%

5%

9.35E-05

Deletion 17 P

68 (10%)

10%

11%

15%

6%

9%

5%

0.06

No major abnormalities

165 (23%)

35%

24%

19%

22%

17%

32%

0.006

Immunophenotypic markers (mean + SD)

CD19

81 (±15)

68 (±19)

78 (±21)

87 (±10)

78 (±13)

77 (±14)

85 (±14)

6.41E-17

CD20

78 (±20)

84 (±21)

80 (±19)

77 (±21)

73 (±20)

78 (±21)

79 (±18)

0.02

CD22

63 (±39)

82 (±32)

70 (±41)

60 (±39)

68 (±36)

79 (±33)

43 (±39)

1.14E-17

CD23

87 (±18)

80 (±27)

89 (±18)

88 (±15)

86 (±22)

88 (±18)

86 (±15)

9.95E-03

CD38

24 (±27)

21 (±27)

36 (±39)

30 (±29)

17 (±22)

21 (±25)

21 (±25)

0.01

CD79b

43 (±38)

50 (±37)

43 (±34)

45 (±31)

39 (±30)

52 (±52)

31 (±28)

2.68E-05

  1. The top part shows the distribution of diagnoses for the overall population (CLL and MSBL cases) and stratified by Signature group. Below that the presented information is based on only the CLL patients. Overall population and CLL Signature group descriptive statistics by diagnosis, age, race, gender, stage, cytogenetics, clinical lab tests, and outcomes. Signature group associations (p-values in right column) were determined by using chi-square and Kruskal–Wallis tests. Numbers represent the average and standard deviation. Percentages were calculated for data that was known. Significant statistical associations are highlighted with bold p-values.
Back to article page